Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256362 | 0.82 | GPR119 (0.49) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL30931005 | 0.81 | KCNH2 (0.47) | GPR119EGLN2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL29182776 | 0.81 | KCNH2 (0.47) | GPR119EGLN2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24989545 | 0.81 | GPR119 (0.47) | GPR119EGLN2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL31652007 | 0.81 | POLB (0.54) | GPR119EGLN2SMARCA2SMARCA4PBRM1 | |
| SCHEMBL26669527 | 0.80 | GPR119 (0.47) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL25248459 | 0.80 | GPR119 (0.47) | GPR119SMARCA2SMARCA4PBRM1CKS1B | |
| SCHEMBL28939463 | 0.79 | GPR119 (0.51) | GPR119EGLN2MAP4K4NR1H2NR1H3 | |
| SCHEMBL13261305 | 0.79 | GPR119 (0.65) | GPR119EGLN2CKS1BSKP1SKP2 | |
| SCHEMBL29232173 | 0.78 | GPR119 (0.47) | GPR119EGLN2SMARCA2SMARCA4PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM5, GRM1, GRM2 | GPR119 90/4885EGLN2 1103/4885SMARCA2 4068/4885 |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM2 | GPR119 90/4885EGLN2 1103/4885SMARCA2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.